|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Cancer Society, . Breast Cancer
Facts and Figures, 2007–2008, May 2009. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2007-2008.pdfMay
21–2021
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miller ME, Muhsen S, Olcese C, Patil S,
Morrow M and Van Zee KJ: Contralateral breast cancer risk in women
with ductal carcinoma in situ: Is it high enough to justify
bilateral mastectomy. Ann Surg Oncol. 24:2889–2897. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gandini S, Guerrieri-Gonzaga A, Puntoni M
and Decensi A: Metformin and breast cancer risk. J Clin Oncol.
31:973–974. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahmadieh H and Azar ST: Type 2 diabetes
mellitus, oral diabetic medications, insulin therapy, and overall
breast cancer risk. ISRN Endocrinol. 2013:1812402013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brower V: Illuminating the diabetes-cancer
link. J Natl Cancer Inst. 104:1048–1050. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suh S and Kim KW: Diabetes and cancer: Is
diabetes causally related to cancer. Diabetes Metab J. 35:193–198.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scheen AJ, Beck E, De Flines J and Rorive
M: Obesity, insulin resistance and type 2 diabetes: Risk factors
for breast cancer. Rev Med Liege. 66:238–244. 2011.(In French).
PubMed/NCBI
|
|
10
|
Pandey A, Forte V, Abdallah M, Alickaj A,
Mahmud S, Asad S and McFarlane SI: Diabetes mellitus and the risk
of cancer. Minerva Endocrinol. 36:187–209. 2011.PubMed/NCBI
|
|
11
|
Vigneri P, Frasca F, Sciacca L, Pandini G
and Vigneri R: Diabetes and cancer. Endocr Relat Cancer.
16:1103–1123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen TW, Liang YN, Feng D, Tao LY, Qi K,
Zhang HY, Wang HX, Lin QS and Kong H: Metformin inhibits
proliferation and promotes apoptosis of HER2 positive breast cancer
cells by downregulating HSP90. J BUON. 18:51–56. 2013.PubMed/NCBI
|
|
13
|
Col NF, Ochs L, Springmann V, Aragaki AK
and Chlebowski RT: Metformin and breast cancer risk: A
meta-analysis and critical literature review. Breast Cancer Res
Treat. 135:639–646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jalving M, Gietema JA, Lefrandt JD, de
Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: Taking away
the candy for cancer. Eur J Cancer. 46:2369–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bodmer M, Meier C, Krähenbühl S, Jick SS
and Meier CR: Long-term metformin use is associated with decreased
risk of breast cancer. Diabetes Care. 33:1304–1308. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song CW, Lee H, Dings RP, Williams B,
Powers J, Santos TD, Choi BH and Park HJ: Metformin kills and
radiosensitizes cancer cells and preferentially kills cancer stem
cells. Sci Rep. 2:3622012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soga M, Ohashi A, Taniguchi M, Matsui T
and Tsuda T: The di-peptide Trp-His activates AMP-activated protein
kinase and enhances glucose uptake independently of insulin in L6
myotubes. FEBS Open Bio. 4:898–904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhuang Y and Miskimins WK: Cell cycle
arrest in Metformin treated breast cancer cells involves activation
of AMPK, downregulation of cyclin D1, and requires p27Kip1 or
p21Cip1. J Mol Signal. 3:182008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hadad SM, Fleming S and Thompson AM:
Targeting AMPK: A new therapeutic opportunity in breast cancer.
Crit Rev Oncol Hematol. 67:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zong M, Fan DD, Lin S, Song YP, Wang ZY,
Ma XL, Qiu WH, Bai YH, Li L and Li S: Anti-cancer activity and
potential mechanism of a novel aspirin derivative. Eur J Pharmacol.
791:137–146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aban M, Siddqui I, Saboor M, Pervez S and
Moatter T: Haplotypes of SNPs associated with COX-2 and their
comparison with histopathological features of breast cancer
patients. J Immuno Ther Cancer. 3:92015. View Article : Google Scholar
|
|
24
|
Dhakal HP, Naume B, Synnestvedt M, Borgen
E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R,
Giercksky KE and Nesland JM: Expression of cyclooxygenase-2 in
invasive breast carcinomas and its prognostic impact. Histol
Histopathol. 27:1315–1325. 2012.PubMed/NCBI
|
|
25
|
Holmes MD, Chen WY, Schnitt SJ, Collins L,
Colditz GA, Hankinson SE and Tamimi RM: COX-2 expression predicts
worse breast cancer prognosis and does not modify the association
with aspirin. Breast Cancer Res Treat. 130:657–662. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Çiriş IM, Bozkurt KK, Başpinar S and
Kapucuoğlu FN: Immunohistochemical COX-2 overexpression correlates
with HER-2/neu overexpression in invasive breast carcinomas: A
pilot study. Pathol Res Pract. 207:182–187. 2011. View Article : Google Scholar
|
|
27
|
Kim HS, Moon HG, Han W, Yom CK, Kim WH,
Kim JH and Noh DY: COX2 overexpression is a prognostic marker for
Stage III breast cancer. Breast Cancer Res Treat. 132:51–59. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Daneau G, Boidot R, Martinive P and Feron
O: Identification of cyclooxygenase-2 as a major actor of the
transcriptomic adaptation of endothelial and tumor cells to cyclic
hypoxia: Effect on angiogenesis and metastases. Clin Cancer Res.
16:410–419. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lyons TR, Borges VF, Betts CB, Guo Q,
Kapoor P, Martinson HA, Jindal S and Schedin P:
Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal
metastasis of postpartum breast cancer. J Clin Invest.
124:3901–3912. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Killian PH, Kronski E, Michalik KM,
Barbieri O, Astigiano S, Sommerhoff CP, Pfeffer U, Nerlich AG and
Bachmeier BE: Curcumin inhibits prostate cancer metastasis in vivo
by targeting the inflammatory cytokines CXCL1 and −2.
Carcinogenesis. 33:2507–2519. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karavitis J, Hix LM, Shi YH, Schultz RF,
Khazaie K and Zhang M: Regulation of COX2 expression in mouse
mammary tumor cells controls bone metastasis and PGE2-induction of
regulatory T cell migration. PLoS One. 7:e463422012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lucci A, Krishnamurthy S, Singh B,
Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K,
Lodhi A, Vincent L and Cristofanilli M: Cyclooxygenase-2 expression
in primary breast cancers predicts dissemination of cancer cells to
the bone marrow. Breast Cancer Res Treat. 117:61–68. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Visscher DW, Pankratz VS, Santisteban M,
Reynolds C, Ristimäki A, Vierkant RA, Lingle WL, Frost MH and
Hartmann LC: Association between cyclooxygenase-2 expression in
atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst.
100:421–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thun MJ, Henley SJ and Patrono C:
Nonsteroidal anti-inflammatory drugs as anticancer agents:
Mechanistic, pharmacologic, and clinical issues. J Natl Cancer
Inst. 94:252–266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luchetti CG, Mikó E, Szekeres-Bartho J,
Paz DA and Motta AB: Dehydroepiandrosterone and metformin modulate
progesterone-induced blocking factor (PIBF), cyclooxygenase 2
(COX2) and cytokines in early pregnant mice. J Steroid Biochem Mol
Biol. 111:200–207. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Elia E, Sander V, Luchetti CG, Solano ME,
Di Girolamo G, Gonzalez C and Motta AB: The mechanisms involved in
the action of metformin in regulating ovarian function in
hyperandrogenized mice. Mol Hum Reprod. 12:475–481. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: Communication from the
international union against cancer and the American Joint Committee
on Cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sabit H, Abdel-Ghany SE, M Said OA,
Mostafa MA and El-Zawahry M: Metformin reshapes the methylation
profile in breast and colorectal cancer cells. Asian Pac J Cancer
Prev. 19:2991–2999. 2018.PubMed/NCBI
|
|
39
|
Yue W, Zheng X, Lin Y, Yang CS, Xu Q,
Carpizo D, Huang H, DiPaola RS and Tan XL: Metformin combined with
aspirin significantly inhibit pancreatic cancer cell growth in
vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and
Bcl-2. Oncotarget. 6:21208–21224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hodges V, Tucci M and Benghuzzi H: The
effects of metformin and EGCG on PANC-1 cell survival. Biomed Sci
Instrum. 51:393–399. 2015.PubMed/NCBI
|
|
41
|
Liu K, Wang G, Ding H, Chen Y, Yu G and
Wang J: Downregulation of metastasis suppressor 1(MTSS1) is
associated with nodal metastasis and poor outcome in Chinese
patients with gastric cancer. BMC Cancer. 10:4282010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hwang JT, Ha J, Park IJ, Lee SK, Baik HW,
Kim YM and Park OJ: Apoptotic effect of EGCG in HT-29 colon cancer
cells via AMPK signal pathway. Cancer Lett. 247:115–121. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Morgensztern D and McLeod HL:
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer
Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Okubo K, Isono M, Asano T and Sato A:
Metformin augments Panobinostat's Anti-bladder cancer activity by
activating AMP-activated protein kinase. Transl Oncol. 12:669–682.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lipscombe LL, Goodwin PJ, Zinman B,
McLaughlin JR and Hux JE: Diabetes mellitus and breast cancer: A
retrospective population-based cohort study. Breast Cancer Res
Treat. 98:349–356. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dowling RJ, Niraula S, Stambolic V and
Goodwin PJ: Metformin in cancer: Translational challenges. J Mol
Endocrinol. 48:R31–R43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen X, Li C, He T, Mao J, Li C, Lyu J and
Meng QH: Metformin inhibits prostate cancer cell proliferation,
migration, and tumor growth through upregulation of PEDF
expression. Cancer Biol Ther. 17:507–514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation-implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Iglesias DA, Yates MS, van der Hoeven D,
Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J,
Bowser J, et al: Another surprise from Metformin: Novel mechanism
of action via K-Ras influences endometrial cancer response to
therapy. Mol Cancer Ther. 12:2847–2856. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sarfstein R, Friedman Y, Attias-Geva Z,
Fishman A, Bruchim I and Werner H: Metformin downregulates the
insulin/IGF-I signaling pathway and inhibits different uterine
serous carcinoma (USC) cells proliferation and migration in
p53-dependent or -independent manners. PLoS One. 8:e615372013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhou Y, Xu JN, Zeng C, Li X, Zhou YF, Qi Y
and Xue Q: Metformin suppresses prostaglandin E2-induced cytochrome
P450 aromatase gene expression and activity via stimulation of
AMP-activated protein kinase in human endometriotic stromal cells.
Reprod Sci. 22:1162–1170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bansal K, Narayana Y and Balaji KN:
Inhibition of TNF-alpha-induced cyclooxygenase-2 expression by
Mycobacterium bovis BCG in human alveolar epithelial A549 cells.
Scand J Immunol. 69:11–19. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zidar N, Odar K, Glavac D, Jerse M, Zupanc
T and Stajer D: Cyclooxygenase in normal human tissues-is COX-1
really a constitutive isoform, and COX-2 an inducible isoform. J
Cell Mol Med. 13:3753–3763. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Rodrigues S, Bruyneel E, Rodrigue CM,
Shahin E and Gespach C: Cyclooxygenase 2 and carcinogenesis. Bull
Cancer. 91:Spec No: S61-S76, 2004 (In French).
|
|
58
|
Jørgensen SB, Jensen TE and Richter EA:
Role of AMPK in skeletal muscle gene adaptation in relation to
exercise. Appl Physiol Nutr Metab. 32:904–911. 2007. View Article : Google Scholar
|
|
59
|
Röckl KS, Witczak CA and Goodyear LJ:
Signaling mechanisms in skeletal muscle: Acute responses and
chronic adaptations to exercise. IUBMB Life. 60:145–153. 2008.
View Article : Google Scholar
|
|
60
|
Huang SP, Wu MS, Shun CT, Wang HP, Hsieh
CY, Kuo ML and Lin JT: Cyclooxygenase-2 increases hypoxia-inducible
factor-1 and vascular endothelial growth factor to promote
angiogenesis in gastric carcinoma. J Biomed Sci. 12:229–241. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cianchi F, Cortesini C, Bechi P, Fantappiè
O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R
and Masini E: Up-regulation of cyclooxygenase 2 gene expression
correlates with tumor angiogenesis in human colorectal cancer.
Gastroenterology. 121:1339–1347. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hadad SM, Baker L, Quinlan PR, Robertson
KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG,
et al: Histological evaluation of AMPK signalling in primary breast
cancer. BMC Cancer. 9:3072009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang T, Wang X, He D, Jin X and Guo P:
Metformin sensitizes human bladder cancer cells to TRAIL-induced
apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
Anticancer Drugs. 25:887–897. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Takabatake M, Daino K, Imaoka T, Nishimura
M, Morioka T, Fukushi M and Shimada Y: Aberrant expression and
phosphorylation of 4E-BP1, a main target of mTOR signaling, in rat
mammary carcinomas: an association with etiology. In Vivo.
25:853–860. 2011.PubMed/NCBI
|
|
65
|
Coleman LJ, Peter MB, Teall TJ, Brannan
RA, Hanby AM, Honarpisheh H, Shaaban AM, Smith L, Speirs V,
Verghese ET, et al: Combined analysis of eIF4E and 4E-binding
protein expression predicts breast cancer survival and estimates
eIF4E activity. Br J Cancer. 100:1393–1399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Akcakanat A, Sahin A, Shaye AN, Velasco MA
and Meric-Bernstam F: Comparison of Akt/mTOR signaling in primary
breast tumors and matched distant metastases. Cancer.
112:2352–2358. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Bort A, Quesada S, Ramos-Torres Á,
Gargantilla M, Priego EM, Raynal S, Lepifre F, Gasalla JM,
Rodriguez-Henche N, Castro A and Díaz-Laviada I: Identification of
a novel 2-oxindole fluorinated derivative as in vivo antitumor
agent for prostate cancer acting via AMPK activation. Sci Rep.
8:43702018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Rehman G, Shehzad A, Khan AL and Hamayun
M: Role of AMP-activated protein kinase in cancer therapy. Arch
Pharm (Weinheim). 347:457–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lee MS, Han HJ, Han SY, Kim IY, Chae S,
Lee CS, Kim SE, Yoon SG, Park JW, Kim JH, et al: Loss of the E3
ubiquitin ligase MKRN1 represses diet-induced metabolic syndrome
through AMPK activation. Nat Commun. 9:34042018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Janzen NR, Whitfield J and Hoffman NJ:
Interactive roles for AMPK and glycogen from cellular energy
sensing to exercise metabolism. Int J Mol Sci. 19:33442018.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
